Millennium Biotechnologies Retains Sports Marketing Firm to Introduce New NCAA Compliant 'Resurgex Fusion' Product to Professional & Collegiate Sports.

BASKING RIDGE, N.J. -- Millennium Biotechnologies (OTCBB:MBTG), manufacturer of Resurgex, a popular line of nutritional supplements in the medical and sports industries, announced today that it has retained the Blake and Bosworth Group, a cutting-edge sports marketing and corporate consulting firm, to help lead the company's marketing and PR efforts as it launches its new NCAA compliant 'Fusion' product into the collegiate and professional sports industry.

The Blake and Bosworth Group, a sports marketing firm that specializes in developing and executing marketing strategies for global consumer brands, will spearhead the Resurgex launch into professional and collegiate sports and the neutraceutical mass market. Blake and Bosworth is led by Dennis Blake and Jamie Bosworth, formerly of the Callaway Golf Company. During their tenure in the golf industry Dennis and Jamie were instrumental in developing and executing several successful product launches at the Odyssey, Ben Hogan and Top-Flite brands. They also pioneered the first-ever cross promotional marketing campaign between NASCAR and the golf industry. "We are excited about the opportunity to assist Millennium Biotechnologies in its effort to expand the brand's reach," said Jamie Bosworth. "Resurgex is a truly unique product that finally answers the call from professional and collegiate athletes for a supplement that is compliant and effective," said James Bosworth.

Designed for the medical community to address fatigue, muscle loss and oxidative stress commonly found in those with immunocompromised conditions, the Resurgex line is now expanding into the collegiate and professional sports sectors. Unlike most other products on the market which load up on excessive amounts of protein and high amounts of sugar and stimulants, Resurgex Fusion is unique in that it delivers a balanced combination of whole food calories and therapeutic levels of important supportive nutrients that aid recovery and improve performance in athletes undergoing rigorous training.

Resurgex Fusion has outperformed the leading nutritional formulas in double blind, placebo controlled trials conducted in both strength and endurance athletes. In addition, each batch of Resurgex Fusion is tested and certified not to contain banned substances by the Banned Substance Control Group's (BSCG) certification program, the only certification program in the U.S. that uses a World Anti Doping Agency (WADA) accredited laboratory to detect for dangerous banned substances in nutritional supplements (please see http://www.stockupticks.com/profiles/12-7-06.html).

The Resurgex line of products finally represents a well thought out, medically accepted and scientifically substantiated formula that address the very nutritional needs of athletes similar to those shared by the chronically ill patient. Several elite athletes have started to take notice, as the products are now being used by numerous professional sporting organizations.

"We could not be happier to have the Blake and Bosworth Group join our team in introducing this advanced product to athletes around the world," said Jerry Swon, President of Millennium Biotechnologies. "Dennis Blake and James Bosworth's experience with launching consumer products in the sports industry is unrivaled. We are excited to team up with them to become the leading innovators in nutritional supplements."

About Millennium Biotechnologies, Inc.

Millennium Biotechnologies, Inc. is a research-based pharmaceutical company and a pioneer in the emerging field of specialized nutritional supplements. The company's flagship products, RESURGEX(r), RESURGEX Plus(r), and RESURGEX Select(r), are designed to assist in reducing fatigue and oxidative stress, maintaining lean muscle and immune support in immunocompromised conditions. In addition, Resurgex products were developed to address the multiple nutritional needs of professional athletes as well as those who are involved in regular exercise programs. Millennium Biotechnologies, Inc. is a wholly owned subsidiary of Millennium Biotechnologies Group, Inc., a publicly-traded company (OTC BB:MBTG.OB - News). For more information about Millennium Biotechnologies, please call Frank Guarino, Chief Financial Officer, at [e-mail] or call [phone]. For more information about the Resurgex line of products visit http://www.resurgex.com.

About The Blake and Bosworth Group

The Blake and Bosworth Group, headquartered in Bernardsville, New Jersey, is a full-service Sports Marketing and Corporate Consulting firm owned and managed by Dennis Blake and James Bosworth, formerly of the Callaway, Top-Flite and Ben Hogan golf companies. The Sports Marketing Group specializes in designing and implementing marketing strategies aimed at maximizing brand awareness by initiating sponsorship and promotional opportunities with various sporting entities including the PGA Tour, the NHL, and NASCAR. The Blake and Bosworth Group place particular emphasis on measuring a client's return on investing in sports marketing by utilizing a proprietary marketing database that benchmarks the results of a client's marketing spend against various models derived from actual marketing investments of Fortune 1000 companies. The Corporate Consulting Group works with sports-centric consumer brands, providing services targeted at improving efficiencies in all areas of business operations including sales, marketing, public relations, product development, manufacturing, R&D and distribution.

Millennium plans to file with the Securities and Exchange Commission and mail to its stockholders a proxy statement which will contain information about Millennium, the sale of its assets and the formation and capitalization of RAC Nutrition (the "Proposed Transaction") and related matters. Stockholders are urged to read the proxy statement carefully when it is available, as it will contain important information that stockholders should consider before making a decision about the Proposed Transaction. In addition to receiving the proxy statement from Millennium by mail, stockholders also will be able to obtain the proxy statement, as well as other filings containing information about Millennium, without charge, from the Securities and Exchange Commission's website (http://www.sec.gov). This announcement is neither a solicitation of proxy, an offer to purchase, nor a solicitation of an offer to sell shares of Millennium. Millennium and its executive officers and directors may be deemed to be participants in the solicitation of proxies from Millennium's stockholders with respect to the Proposed Transaction. Information regarding any interests that Millennium's executive officers and directors may have in the Proposed Transaction will be set forth in the proxy statement.

This release includes certain forward-looking information that is based upon management's beliefs as well as on assumptions made by and data currently available to management. This information which has been, or in the future may be, included in reliance on the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, is subject to a number of risks and uncertainties, including but not limited to uncertainty as to market acceptance of our products and the factors identified in the Company's 10-KSB and other documents filed with the Securities and Exchange Commission. Actual results may differ materially from those anticipated in such forward-looking statements even if experience or future changes make it clear that any projected results expressed or implied therein may not be realized. The Company undertakes no obligation to update or revise any forward-looking statements to reflect subsequent events or circumstances.